Needham analyst Joseph Stringer has maintained their bullish stance on VIR stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Stringer has given his Buy rating due to a combination of factors related to Vir Biotechnology’s promising developments in their Hepatitis Delta Virus (HDV) and oncology programs. The company’s focus on advancing its Ph3 HDV program, with significant data expected from three registrational trials by the first quarter of 2027, positions it well in a market estimated to be worth $1.5-2 billion, potentially more with increased diagnosis rates.
Additionally, Vir’s early-stage T-cell engager oncology programs, particularly the expansion of VIR-5500 in its Phase 1 trial, demonstrate a commitment to innovation and growth in the oncology sector. These strategic advancements, coupled with a robust cash balance of $811 million as of the third quarter of 2025, provide a solid foundation for future success and justify the Buy rating.